UCB SA (OTCMKTS:UCBJY – Get Free Report) gapped up before the market opened on Tuesday. The stock had previously closed at $114.20, but opened at $119.47. UCB shares last traded at $120.66, with a volume of 8,702 shares changing hands.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the stock. Jefferies Financial Group upgraded shares of UCB from a “moderate sell” rating to a “hold” rating in a research report on Monday, August 3rd. Zacks Research downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy”.
Read Our Latest Research Report on UCBJY
UCB Stock Performance
The business has a 50 day moving average of $120.68 and a 200-day moving average of $134.92.
About UCB
UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases in neurology and immunology. The company serves patients and healthcare professionals internationally, with operations and commercial activities spanning Europe, North America and other global markets.
UCB’s neurology portfolio includes medicines such as Vimpat (lacosamide) and Briviact (brivaracetam) for epilepsy, as well as Fintepla (fenfluramine) for certain seizure disorders.
See Also
- Five stocks we like better than UCB
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
